Benefits are currently only available to people approved to join the trial & those who go onto the stock early.
"On Wednesday, just hours after Trump praised the drug as the “cure” for the virus, Regeneron announced that it submitted an application to the Food and Drug Administration’s (FDA) for an emergency use authorization of the drug, which is a cocktail mix of two antibodies meant to aid the immune system in fighting the virus.
Regeneron’s stock, and the stock of Eli Lilly, another pharmaceutical company conducting drug trials for an anti-body treatment, soared Thursday after Trump touted the treatment.
“The politics of the situation would suggest to me that the story could be Trump gets Covid … then American technology fostered by the Trump administration cures Covid,” said Dr Dirk Sostman, head of research network at Houston Methodist Hospital, a trial site for Regeneron’s antibody program, who told Reuters that more patients were seeking to take part in the trial. “I would think there would be pressure on regulators [to approve the drug],” he said.'
"Because the drug is in clinical trials, it is only available to patients who are accepted into the trial.
With approval from the FDA, drug companies can offer a treatment to patients not participating in trials under “compassionate use” rules, which are meant to make treatments accessible to patients with a life-threatening condition that has no alternative therapies available.
Regeneron said that under 10 people have been given its drug under the rules."
